Medicinal cannabis users perceive a significant improvement in insomnia with cannabinoid use, and this study suggests a possible advantage with the use of predominant indica strains compared with predominant sativa strains and exclusively CBD in this population. Overall (cannabinoids were perceived to be efficacious across all genders and ages), and no significant differences were found among product forms, ingestion methods, or gender groups. Our analyses examined 991 medicinal cannabis users with insomnia across 24,189 tracked cannabis use sessions.

Animal studies demonstrated that manipulation of the ECB system altered activity and cognitive function, some of which appeared to be dependent on the light/dark cycle. This review aims to summarize the recent literature on the ECB system, the role of cannabis and the ECB system on sleep regulation and cognition. Future research on PEA must aim to uncover the intricate biochemical mechanisms linking the activity of peroxisome proliferator-activated receptors (PPARs) to the intricate transmitter systems that govern sleep architecture and the regulation of the sleep–wake rhythm.

In one study REM sleep was increased in response to increased AEA , Méndez-Díaz et al., 2013,. Additionally — the authors used an event-related fMRI card-guessing paradigm to how different weed strains compare measure reward pathway activation. There was variability in the cannabis content used by participants in this study, as well as substantial differences in cannabis use frequency and method of use.

AASM condemns House passage of Sunshine Protection Act

To understand how cannabis-based medical products might affect insomnia symptoms, the authors of this study analyzed a set of 124 insomnia patients taking medical cannabis products. Prevalence and correlates of sleep-related problems in adults receiving medical cannabis for chronic pain. Specifically, the obtained data were from a large sample of medical cannabis users who use a variety of cannabis products for a variety of sleep-related issues.

The authors would like to express their deep appreciation to the staff and clinicians at Wholeness Center for their professionalism. The first is that in our experience lower doses appear to elicit an adequate clinical response. The treatment with CBD was in general well accepted, as judged by the clinicians’ and patients’ responses. These results demonstrated a more sustained response to anxiety than for sleep over time. Mean anxiety and sleep scores for adults using cannabidiol treatment.

The conclusion drawn by the authors from this data is that individuals with comorbid PTSD and SUD do not require a period of abstinence before tackling their PTSD. Data from Strainprint, a medical cannabis application, was utilized in one observational study where users documented their symptoms of depression, anxiety, and stress, tracking changes over time. A significant drawback of this study is the lack of investigation into dose-response relationships. Nevertheless, high heterogeneity and an outlier study constrain this research. Nevertheless — this study faces limitations due to its considerable heterogeneity.

Conducted in Canada — three studies (two RCTs) primarily involving male participants indicated either improved sleep quality or no significant changes, with variable effects on total sleep and nightmares in individuals taking nabilone. The relationship between cannabis, sleep, and post-traumatic stress disorder is presented in Table 5. Table 4 illustrates that 75% of the studies on cannabis as an alternative treatment for insomnia and chronic pain were randomized controlled trials (while 25% were cross-sectional), with findings evenly distributed between North America and Europe. Observational studies examining the impact of cannabis on sleep are listed in the order of their publication. The chronological order of publication showcases experimental studies that explore the effect of cannabis on sleep.